Peter Hillmen, MD, PhD

Professor of Experimental Haematology
University of Leeds
St. James University Hospital, United Kingdom

Poster(s):

• 1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.

• 1223 - Depletion of normal B-cells, defined as < 20 cells/µL by high-sensitivity analysis, identifies early-stage CLL and MBL patients at increased risk of severe infection and early mortality.

• 1415 - Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial

• 1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

• 1437 - Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial